AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2022
Dec 30, 2022
31523_dirs_2022-12-30_01486beb-2226-4d32-9f41-acf166dbb2ff.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2022-12-21
Reporting Person: Castelli Jeff (Chief Development Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 304255 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Options (right to buy) | $12.28 | 2025-06-01 | Common Stock (50000) | Direct | |
| Stock Options (right to buy) | $9.03 | 2026-01-04 | Common Stock (50000) | Direct | |
| Stock Options (right to buy) | $15.67 | 2028-01-03 | Common Stock (39762) | Direct | |
| Stock Options (right to buy) | $10.04 | 2029-01-02 | Common Stock (82644) | Direct | |
| Stock Options (right to buy) | $9.55 | 2030-01-02 | Common Stock (107575) | Direct | |
| Stock Options (right to buy) | $21.78 | 2031-01-04 | Common Stock (46396) | Direct | |
| Stock Options (right to buy) | $12.11 | 2032-01-03 | Common Stock (108266) | Direct |
Footnotes
F1: Includes 161,910 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Amicus common stock.
F2: All of the options in this row are fully vested and exercisable as of December 21, 2022.
F3: The options reported in this row were granted on January 2, 2019 and become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 80,896 of such options were fully vested and exercisable and 1,748 remained unvested.
F4: The options reported in this row were granted on January 2, 2020 and become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 78,436 of such options were fully vested and exercisable and 29,139 remained unvested.
F5: The options reported in this row were granted on January 4, 2021 and become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 22,225 of such options were fully vested and exercisable and 24,171 remained unvested.
F6: The options reported in this row were granted on January 3, 2022 and will become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 0 of such options were fully vested and exercisable and 108,266 remained unvested.